Brenig Therapeutics, a Dover, DE-based neurology-focused drug development company utilizing an AI/ML-based discovery platform, raised $65M in Series A funding.
The round was led by NEA, with participation from OrbiMed, Torrey Pines Investments and BioGeneration Ventures. In connection with the financing, Ed Mathers, Partner at NEA, will join the Board of Directors.
The company intends to use the funds to advance BT-267 through healthy volunteer studies and into proof-of-concept studies in idiopathic Parkinson’s disease patients.
Led by CEO Iain Dukes MA DPhil, Chairman, Brenig is a small molecule drug development company that utilizes an AI/ML approach via a partnership with Expert Systems Inc., a drug accelerator that has spawned multiple clinical candidates across multiple therapeutic areas.
Its BT-267 is a small molecule LRKK2 inhibitor designed to have a PK profile that allows for high and sustained brain exposure and minimal peripheral exposure, thus ensuring superior efficacy while minimizing on-target and off-tissue toxicity.
FinSMEs
23/07/2024